AEI is rereleasing some of its most prescient and groundbreaking works from its earliest thinkers and innovators. These books, part of a series called AEI Classics, are available for download as Adobe Acrobat PDFs.
The growth of government programs and managed care has altered how pharmaceuticals are marketed and sold in the United States. Such change has shortened the expected revenue stream from most products--even though new technologies have increased both the cost and the medical attractiveness of those products.
Managers of government and private health care programs are looking for new ways to reduce the cost of drug benefits, while company R&D managers are seeking ways to speed the regulatory process and develop new markets to cover the increasing cost of research.
This volume examines various aspects of the continuing policy dispute and offers several views on the future of the pharmaceutical industry.
Robert B. Helms is a resident scholar at AEI.
Table of Contents
Introduction
Generics and the Producer Price Index for Pharmaceuticals
An Updated and Extended Study of the Price Growth of Prescription Pharmaceutical Preparations
Measuring Quality Change in the Market for Anti-Ulcer Drugs
The Uses and Abuses of International Price Comparisons
Industrial Policy and International Competitiveness in the Pharmaceutical Industry
R&D Productivity and Global Market Share in the Pharmaceutical Industry
The Determinants of Research Productivity in Ethical Drug Discovery
Prospects for Returns to Pharmaceutical R&D under Health Care Reform
Measuring Pharmaceutical Industry Risk and the Cost of Capital
The Effects of Research and Promotion on Rates of Return
New Uses for Old Drugs
The Leverage Principle in FDA's Regulation of Information
Costs and Benefits of Cost-Benefit Analysis in Pharmaceutical Promotion and Utilization Decisions
What lies ahead for Cuba after Castro? Mark Falcoff writes that an economically unviable and otherwise dysfunctional Cuba could in coming years pose an even bigger threat to the United States than in its communist heyday.
The promise of "healthy aging" offers significant opportunities for economic growth and development for Europe in the decades ahead--if governments and citizens are willing to grasp them.
